Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Annals of neurology·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026
Same author

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jun 5, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

DNA-based vaccines for multiple sclerosis: current status and future directions.

Nicolas Fissolo1, Xavier Montalban, Manuel Comabella

  • 1Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica,Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain.

Clinical Immunology (Orlando, Fla.)
|December 18, 2010
PubMed
Summary

DNA vaccination shows promise for treating multiple sclerosis (MS) by inducing immune tolerance, offering a safer alternative to current therapies. Clinical trials in MS patients demonstrate reduced disease activity and antigen-specific tolerance.

More Related Videos

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: Jun 5, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

  • Neuroimmunology
  • Vaccine Technology
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a chronic, disabling central nervous system inflammatory disease affecting young adults.
  • Current immunosuppressive therapies for MS have limited efficacy and significant adverse effects.
  • DNA vaccination, a gene-based immunization strategy, can modulate immune responses.

Purpose of the Study:

  • To review the efficacy of DNA vaccination in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE).
  • To discuss the potential of DNA vaccines as a safer therapeutic strategy for MS.
  • To explore optimization strategies for DNA vaccine technology in MS treatment.

Main Methods:

  • Review of existing data from experimental autoimmune encephalomyelitis (EAE) studies.
  • Analysis of phase I and II clinical trials involving DNA vaccines in patients with relapse-onset MS.
  • Examination of immune tolerance mechanisms induced by DNA vaccination.

Main Results:

  • DNA vaccination has demonstrated efficacy in inhibiting experimental autoimmune encephalomyelitis (EAE) through induction of immune tolerance.
  • Clinical trials in MS patients showed reduced MRI-measured disease activity.
  • DNA vaccines induced antigen-specific tolerance in myelin-specific B and T cells in MS patients.

Conclusions:

  • DNA vaccination is a promising therapeutic approach for multiple sclerosis (MS).
  • This strategy appears to overcome safety concerns associated with other MS therapies.
  • Further optimization of DNA vaccine technology could enhance treatment efficacy for MS.